» Articles » PMID: 32964440

Comprehensive Landscape of STEAP Family Functions and Prognostic Prediction Value in Glioblastoma

Overview
Journal J Cell Physiol
Specialties Cell Biology
Physiology
Date 2020 Sep 23
PMID 32964440
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Glioblastoma (GBM) is the most common, malignant, and deadly primary glioma. Six-transmembrane epithelial antigen of prostate (STEAP) family is involved in tumorigenesis; here, we have explored the biological function and the prognostic value of the STEAP family in GBM. Differentially expressed STEAP genes in tumor and normal samples were screened by using The Cancer Genome Atlas (TCGA) database. Univariate and multivariate Cox regression identified the prognosis-related genes: STEAP2 and STEAP3, which were involved in the regulation of immune response and cell cycle. Finally, a prognostic nomogram combining age, gender, chemotherapy, radiotherapy, IDH1 status, and the risk score model based on STEAP2 and STEAP3 was built and further validated in TCGA and Chinese Glioma Genome Atlas (CGGA) cohorts via concordance index and calibration plot, which suggested a favorable value for prognosis prediction. In conclusion, our results provided a comprehensive analysis of the STEAP family and a model for the prognosis prediction of GBM.

Citing Articles

Copper in the colorectal cancer microenvironment: pioneering a new era of cuproptosis-based therapy.

Feng Q, Sun Y, Yang Z, Wang Z, Chen Z, Liu F Front Oncol. 2025; 14():1522919.

PMID: 39850821 PMC: 11754209. DOI: 10.3389/fonc.2024.1522919.


Targeting ferroptosis opens new avenues in gliomas.

Wei Y, Xu Y, Sun Q, Hong Y, Liang S, Jiang H Int J Biol Sci. 2024; 20(12):4674-4690.

PMID: 39309434 PMC: 11414377. DOI: 10.7150/ijbs.96476.


Nomograms for prognosis prediction in esophageal adenocarcinoma: realities and challenges.

Zheng H, Wu R, Zhang G, Wang Q, Li Q, Zhang L Clin Transl Oncol. 2024; 27(2):449-457.

PMID: 39083141 DOI: 10.1007/s12094-024-03589-z.


Histone acetylation risk model predicts prognosis and guides therapy selection in glioblastoma: implications for chemotherapy and anti-CTLA-4 immunotherapy.

Jin X, Qin Z, Zhao H BMC Immunol. 2024; 25(1):51.

PMID: 39068393 PMC: 11282667. DOI: 10.1186/s12865-024-00639-7.


Deciphering glycosylation-driven prognostic insights and therapeutic prospects in glioblastoma through a comprehensive regulatory model.

Jin X, Chen Z, Zhao H Front Oncol. 2024; 14:1288820.

PMID: 38841168 PMC: 11150821. DOI: 10.3389/fonc.2024.1288820.